Humana (NYSE:HUM) Upgraded to “Hold” at Zacks Research

Humana (NYSE:HUM) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other research firms also recently issued reports on HUM. Evercore dropped their price objective on shares of Humana from $260.00 to $180.00 in a report on Thursday, February 12th. UBS Group reaffirmed a “neutral” rating on shares of Humana in a report on Wednesday, February 25th. Robert W. Baird dropped their price target on shares of Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a research note on Thursday, December 11th. Truist Financial cut their price objective on shares of Humana from $285.00 to $200.00 and set a “hold” rating for the company in a research report on Tuesday, February 17th. Finally, Deutsche Bank Aktiengesellschaft set a $180.00 price objective on Humana and gave the stock a “hold” rating in a research note on Friday, February 13th. Seven investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $225.48.

Humana Stock Down 0.8%

Humana stock opened at $179.27 on Thursday. Humana has a one year low of $169.61 and a one year high of $315.35. The stock has a fifty day moving average of $221.75 and a 200 day moving average of $252.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a market cap of $21.62 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 1.95 and a beta of 0.44.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The business’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same period last year, the firm posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, sell-side analysts predict that Humana will post 16.47 EPS for the current year.

Insider Activity at Humana

In other Humana news, insider Sanjay K. Shetty purchased 810 shares of Humana stock in a transaction that occurred on Monday, February 23rd. The shares were bought at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the transaction, the insider owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.37% of the company’s stock.

Hedge Funds Weigh In On Humana

Institutional investors have recently bought and sold shares of the business. Montag A & Associates Inc. grew its stake in shares of Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after buying an additional 94 shares in the last quarter. CoreCap Advisors LLC raised its position in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Fideuram Asset Management Ireland dac bought a new position in shares of Humana in the 4th quarter valued at about $27,000. Reflection Asset Management purchased a new position in Humana in the fourth quarter worth about $29,000. Finally, Rosenberg Matthew Hamilton grew its position in Humana by 136.0% in the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after acquiring an additional 68 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.